Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
Shilpa Medicare Financial Highlights
- Revenue: Shilpa Medicare reported revenue of ₹1,548.71 crore in FY26 vs ₹1,309.76 crore in FY25. It showed an increase of 18.24% on a yearly basis.
- Operating Profit: Shilpa Medicare reported an operating profit of ₹295.31 crore in FY26 vs ₹122.33 crore in FY25. It showed an increase of 141.40% on a year-on-year basis.
- Net Profit: Shilpa Medicare reported a net profit of ₹243.33 crore in FY26 vs ₹78.29 crore in FY25. It showed an increase of 210.81% on a yearly basis.
Shilpa Medicare Quarterly Result Highlights
- Shilpa Medicare reported revenue of ₹438.66 crore in Mar 2026, compared with ₹410.54 crore in Dec 2025, representing an increase of 6.85% on a quarter-on-quarter (QoQ) basis.
- Shilpa Medicare reported an operating profit of ₹120.44 crore in Mar 2026, compared with ₹60.85 crore in Dec 2025, representing an increase of 97.93% on a quarter-on-quarter (QoQ) basis.
- Shilpa Medicare reported a profit of ₹107.79 crore in Mar 2026, compared with ₹44.58 crore in Dec 2025, reflecting an increase of 141.79% on a QoQ basis.
- The earnings per share (EPS) of Shilpa Medicare stood at ₹8.04 during Mar 2026.
